The Splice Index as a prognostic biomarker of strength and function in myotonic dystrophy type 1
Journal of Clinical Investigation · 17.02.2025 · 135 (4)
DOI: 10.1172/jci185426 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Clinical Investigation, online erschienen am 07.01.2025. Verfasst von Marina Provenzano und 15 weiteren Autor:innen. Beteiligte Einrichtung: Center for Inherited Myology Research and. Hauptthemen laut MEDLINE: Muscle Strength, Muscle, Skeletal, Myotonic Dystrophy, RNA Splicing. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: FDA HHS, U.S. Food and Drug Administration, Myotonic Dystrophy Foundation.
Abstract (Originalsprache)
BACKGROUND Myotonic dystrophy type 1 (DM1) is a multisystemic, CTG repeat expansion disorder characterized by a slow, progressive decline in skeletal muscle function. A biomarker correlating RNA mis-splicing, the core pathogenic disease mechanism, and muscle performance is crucial for assessing response to disease-modifying interventions. We evaluated the Myotonic Dystrophy Splice Index (SI), a composite RNA splicing biomarker incorporating 22 disease-specific events, as a potential biomarker of DM1 muscle weakness. METHODS Total RNA sequencing of tibialis anterior biopsies from 58 DM1 participants and 33 unaffected/disease controls was used to evaluate RNA splicing events across the disease spectrum. Targeted RNA sequencing was used to derive the SI from biopsies collected at baseline ( n = 52) or a 3-month ( n = 37) follow-up visit along with clinical measures of muscle performance. RESULTS The SI demonstrated significant associations with measures of muscle strength and ambulation, including ankle dorsiflexion (ADF) strength and 10-meter run/fast walk (Pearson’s r = –0.719 and –0.680, respectively). The SI was relatively stable over 3 months (intraclass correlation coefficient [ICC] = 0.863). Latent-class analysis identified 3 DM1 subgroups stratified by baseline SI (SI Mild , SI Moderate , and SI Severe ); SI Moderate individuals had a significant increase in the SI over 3 months. Multiple linear regression modeling revealed that baseline ADF and SI were predictive of strength at 3 months (adjusted R ² = 0.830). CONCLUSION The SI is a reliable biomarker that captures associations of RNA mis-splicing with physical strength and mobility and has prognostic utility to predict future function, establishing it as a potential biomarker for assessment of therapeutic target engagement. TRIAL REGISTRATION ClinicalTrials.gov NCT03981575. FUNDING FDA (7R01FD006071), Myotonic Dystrophy Foundation, Wyck Foundation, Muscular Dystrophy Association, Novartis, Dyne, Avidity, PepGen, Takeda, Sanofi Genzyme, Pfizer, Arthex, and Vertex Pharmaceuticals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Inherited Myology Research and.
- Department of Neurology, School of Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.
- Children's Hospital of Richmond at Virginia Commonwealth University, Pediatric Therapy Services, Richmond, Virginia, USA.
- Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.
- College of Dental Medicine, Roseman University of Health Sciences, South Jordan, Utah, USA.
- Department of Orthopaedics, University of Utah, Salt Lake City, Utah, USA.
Förderung
- FDA HHS
- U.S. Food and Drug Administration
- Myotonic Dystrophy Foundation
- Wyck Foundation
- Muscular Dystrophy Association
- Novartis
- Dyne
- Avidity
Zitieren
APA
Provenzano, M., Ikegami, K., Bates, K., Gaynor, A., Hartman, J. M., Jones, A., Butler, A., Berggren, K. N., Dekdebrun, J., Hung, M., Lapato, D. M., Kiefer, M., Thornton, C. A., Johnson, N. E., Hale, M. A., & Myotonic Dystrophy Clinical Research Network (DMCRN) (2025). The Splice Index as a prognostic biomarker of strength and function in myotonic dystrophy type 1. Journal of Clinical Investigation, 135(4). https://doi.org/10.1172/jci185426
Vancouver
Provenzano M, Ikegami K, Bates K, Gaynor A, Hartman JM, Jones A, et al. The Splice Index as a prognostic biomarker of strength and function in myotonic dystrophy type 1. Journal of Clinical Investigation. 2025;135(4). doi:10.1172/jci185426
BibTeX
@article{Provenzano2025,
author = {Provenzano, Marina and Ikegami, Kobe and Bates, Kameron and Gaynor, Alison and Hartman, Julia M and Jones, Aileen and Butler, Amanda and Berggren, Kiera N and Dekdebrun, Jeanne and Hung, Man and Lapato, Dana M and Kiefer, Michael and Thornton, Charles A and Johnson, Nicholas E and Hale, Melissa A and Myotonic Dystrophy Clinical Research Network (DMCRN), Myotonic Dystrophy Clinical Research Network (DMCRN)},
title = {The Splice Index as a prognostic biomarker of strength and function in myotonic dystrophy type 1},
journal = {Journal of Clinical Investigation},
year = {2025},
volume = {135},
number = {4},
doi = {10.1172/jci185426}
}
EUVIMED